+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05267626

Study of AU-007, a Monoclonal Antibody Targeting IL-2, Evaluated Alone and with Aldesleukin, Avelumab, or Nivolumab in Patients with Unresectable Advanced or Metastatic Cancer

Led by Aulos Bioscience, Inc. · Updated on 2026-09-18

159

Participants Needed

17

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating AU-007, also called imneskibart, in patients with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. This first-in-human, open-label Phase 12 study aims to assess the safety, tolerability, and initial effectiveness of AU-007 alone or combined with aldesleukin, with further combinations including avelumab or nivolumab. Participants must have measurable disease and have progressed on or be ineligible for standard treatments. The study includes multiple parts with escalating doses of AU-007 given every two weeks, either alone or with aldesleukin in different dosing schedules. After determining the recommended dose, AU-007 combined with aldesleukin is also tested alongside avelumab or nivolumab in specific patient groups. Treatment is administered in cycles, and different expansion arms focus on particular cancers such as cutaneous melanoma and non-small cell lung cancer. Participants undergo regular assessments including imaging scans to measure disease, blood tests to monitor drug levels and immune response, and safety evaluations throughout treatment and up to 28 days after the last dose. Researchers measure the safety and tolerability of the drugs, establish the maximum tolerated dose, and evaluate early signs of anti-tumor activity. The study monitors participants closely during treatment and follow-up to understand the effects and potential risks of these combinations.

CONDITIONS

Brief Title

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Research Team

J

Jim Vasselli, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here